Stem cell therapy improves condition of patients with type 2 diabetes

06/19/2014 | Australian Life Scientist

Type 2 diabetes patients who were treated with infusions of Mesoblast's mesenchymal precursor cells had greater reductions in blood sugar levels than those who received a placebo, according to a study presented at a meeting of the American Diabetes Association. The 61-patient midstage trial found that the cells were well-tolerated and that treatment was associated with a dose-dependent improvement in glycemic control.

View Full Article in:

Australian Life Scientist

Published in Briefs:

SmartBrief Job Listings for Health Care

Job Title Company Location
MGR POST MARKET STUDIES - 14000001LK
Abbott
Santa Ana, CA
Regulatory Analyst
Delta Dental
Alpharetta, GA
Eastern Zone Sales Director
Regenesis Biomedical
White Plains, NY
Senior Financial Analyst - Growing Manager Care Health Org
Fallon Community Health Plan
Worcester, MA
Associate Director, Regulatory Affairs - Promotional Review
Novo Nordisk
Princeton, NJ